Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cardiology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cardiology Other
    Distinguishing Mutations From Rare Variants Key to Interpreting Genetic Testing in LQTS - (DGNews)
    Small Increases In Phosphorus May Mean Higher Risk of Heart Disease - (DGNews)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    ACC Revises Guidelines for Perioperative Use of Beta Blockers - (DGNews)
    Effect of tailored practice and patient care plans on secondary prevention of heart disease in general practice: cluster randomised controlled trial - (BMJ)

    News archive

     Recent webcasts/CME - Cardiology Other
      Comorbidity in Patients with Rheumatoid Arthritis: What are the Real Concerns?
      Sleep Apnea and the Importance of Patient Screening
      Patient-Centered Approaches to the Evaluation and Management of Atrial Fibrillation
      Current Concepts and Management Strategies in Atrial Flutter
      Cancer, Liver, Infections, Cardiovascular Disease, and other Biologic Agents

      Webcasts/CME archive

       Recent cases - Cardiology Other
        Multiorgan Paradoxical Embolism Consequent to Acute Pulmonary Thromboembolism with Patent Foramen Ovale: A Case Report
        A Long-Term Follow-Up of a Girl With Dilated Cardiomyopathy After Mitral Valve Replacement and Septal Anterior Ventricular Exclusion
        Cardiac Injuries in Blunt Chest Trauma
        Nonsurgical Management of a Tricuspid Valvular Pedunculated Papillary Fibroelastoma
        Atypical Atrial Myxomas in Two Asymptomatic Patients: A Case Report

        Cases archive
          




        my personal edition > cardiology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Revascularised Patients Benefit From More Aggressive Lipid Lowering: Presented at EAS

          By Sara Freeman

          ISTANBUL, Turkey -- May 2, 2008 -- Patients who are treated with an 80-mg rather than a 10-mg dose of atorvastatin after surgery or stenting for coronary heart disease (CHD) are less likely to experience a subsequent cardiovascular (CV) event, according to a post hoc analysis presented here at the 77th Congress of the European Atherosclerosis Society (EAS 2008).

          These findings, from a post hoc analysis of the Treating to New Targets (TNT) study, added further support to the concept of "lower is better" when it comes to targeting low-density lipoprotein cholesterol (LDL-C).

          David Waters, MD, Chief, Division of Cardiology, San Francisco General Hospital, and Professor of Medicine in Residence, University of California, San Francisco, California, presented the findings in a poster presentation on April 28.

          In the original TNT study, patients with CHD who underwent intensive LDL-C lowering to a level of 2.0 mmol/L (77 mg/dL) with atorvastatin 80 mg/day achieved additional clinical benefit beyond that seen in patients who achieved LDL-C reductions to 2.6 mmol/L (101 mg/dL) with atorvastatin 10 mg/day (LaRosa JC et al. Am J Cardiol. 2004;93:154-158).

          Dr. Waters and colleagues conducted their post hoc analysis to see if there was any benefit of using an aggressive lipid-lowering approach after percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or a combination of the 2 procedures.

          Of the 10,001 patients in the TNT study, a total of 3,951 patients had undergone PCI, 3,198 had CABG, and 1,456 had undergone both procedures before entering the TNT study.

          After a median follow-up of 4.9 years, significantly fewer patients treated with the higher-dose of statin experienced a first major CV event (CHD death, nonfatal myocardial infarction [MI], resuscitated cardiac arrest, or stroke) compared with those who received the lower dose.

          Among patients in the PCI group, 8.6% of those given atorvastatin 80 mg had a major CV event versus 10.6% of those who received the 10-mg dose (P = .008). This represented an absolute risk reduction of 2.1%.

          In patients who had undergone CABG, the incidence of a major CV event was 9.7% in the high-dose group and 13.5% in the low-dose group (P = .0004). This represented an absolute risk reduction of 3.8%.

          It is important to note that the incidence of repeat revascularisation was also significantly reduced among patients in the CABG group (P < .0001) and the PCI group (P < .0001).

          Dr. Waters and colleagues concluded that the incidence of major CV events was significantly higher among the patients who had undergone CABG before being enrolled in the TNT study compared with those who had undergone PCI.

          While CABG and PCI both were associated with a high risk of major CV events, patients who had undergone CABG were in particular danger of experiencing a subsequent event. However, intensive lipid lowering with the 80-mg dose of atorvastatin was able to reduce significantly the rate of primary CV events in both CABG and PCI patients compared with the 10-mg dose.

          "In all patients with previous revascularisation, LDL-C should be lowered aggressively to reduce CV events," the researchers advised.

          Funding for the TNT study was provided by Pfizer.


          [Presentation title: Effect of Intensive Cholesterol Lowering With Atorvastatin 80 mg in Patients With Previous Revascularization: A Treating to New Targets (TNT) Substudy. Abstract PO48-738]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send